Notification
THANK YOU FOR MAKING AN APPOINTMENT AT AIH.
Would you like to pre-register?
Please fill in the information below
Urgent
EARLY SCREENING FOR 110 TYPES OF CANCER: AIH PIONEERS THE INTRODUCTION OF CANCERSCREENDX™ – A TEST PERFORMED 100% AT AN INTERNATIONAL STANDARD LABORATORY IN MALAYSIA
In Vietnam, up to 70% of cancer cases are detected only when they have progressed to late stages (stages III-IV) [1]. Late detection means that malignant cells have already extensively invaded or metastasized, which limits intervention methods and significantly reduces the chances of successful recovery [1]. Conversely, reports from the American Cancer Society indicate that if diagnosed and treated proactively at an early stage (stages I-II, when the tumor is still localized), the 5-year survival rate for patients can reach over 90% for most common types of cancer.[2]
To address this significant challenge, the American International Hospital (AIH) has solidified its position as a leader in preventive healthcare by becoming the first institution in Vietnam to offer the CancerScreenDx™ test - a groundbreaking liquid biopsy solution capable of early screening for over 110 types of cancer through a single blood sample collection.
From the professional perspectives of oncologists, laboratory experts, and medical communication specialists, the following are the superior advantages that make CancerScreenDx™ a high-value, high-class genetic cancer screening solution.
1. INTERNATIONAL QUALITY STANDARDS: 100% OF BLOOD SAMPLES ARE TRANSFERRED AND ANALYZED DIRECTLY AT A CAP-ACCREDITED (USA) LABORATORY IN MALAYSIA
Closed-loop international sample shipping process: To ensure maximum objectivity and precision, all customer blood samples collected at AIH are technically processed, strictly preserved, and transported via direct air freight to the central laboratory of AGTC Genomics in Kuala Lumpur, Malaysia, for analysis.
Achieving the global gold standard certification (CAP): The central laboratory of AGTC Genomics in Malaysia is honored to hold the prestigious CAP (College of American Pathologists) certification issued by the College of American Pathologists. This is the most rigorous medical quality accreditation standard in the world, typically applied only at leading hospitals and genetic research centers in the United States and Europe to ensure the superior accuracy of molecular biology analysis results. Simultaneously, this laboratory also possesses other international quality management certifications such as ISO 15189 and ISO 17025.
2. THE POWER OF ULTRA-DEEP ctDNA TECHNOLOGY – ACCURATE AND COMPLETELY DIFFERENT IN THE MARKET
Cells in the body, including both healthy cells and cancer cells, continuously release small fragments of DNA into the circulatory system, known as cell-free DNA (cfDNA/ctDNA) [4]. Applying this biological principle, CancerScreenDx™ utilizes Ultra-Deep Next-Generation Sequencing technology combined with artificial intelligence (AI) to deeply analyze mutation markers and epigenetic methylation traces characteristic of malignant cells [3]. This technology offers superior breakthroughs compared to traditional screening tests:
Broad-spectrum screening for over 110 types of cancer: Traditional screening tests often focus on a single organ or are limited to a few common types of cancer. CancerScreenDx™ expands the scope of protection by having the capability to simultaneously screen for over 110 different cancer strains across 20 major organ groups. This test is particularly valuable in detecting dangerous cancers that progress silently and lack standard routine screening methods (such as pancreatic, ovarian, esophageal, and biliary tract cancers).
Precise Tissue of Origin (TOO) identification: Upon detecting cancer signals in the blood, machine learning algorithms combined with the system's big data analyze methylation patterns to accurately predict the primary site of the tumor in the body [6]. Consequently, clinicians can immediately order targeted diagnostic imaging (such as CT scans, MRI, or direct endoscopic examinations) without wasting time on aimless, broad-spectrum screening.
Mutation-Specific Insights: Instead of merely returning qualitative risk warning levels like 'high' or 'low' which can easily cause confusion, CancerScreenDx™ provides detailed reports on specific gene mutation variants that drive tumor development [3]. This is an invaluable source of medical information that assists oncologists in building precise, personalized treatment regimens for each patient.
3. STRONG CLINICAL EVIDENCE FROM OBJECTIVE INTERNATIONAL STUDIES
The medical quality and reliability of CancerScreenDx™ are not merely based on technological theory but have been empirically proven through large-scale clinical research projects published internationally:
Excellent sensitivity and specificity: A multi-center clinical validation study conducted on a large sample size of 2,342 cancer patients and 1,646 healthy controls (reported at the American Association for Cancer Research - AACR Annual Meeting) demonstrates that the test achieves an overall sensitivity of up to 83.1% and an outstanding specificity of 95.4% [3]. The extremely low false-positive rate of only 4.6% helps to minimize unnecessary anxiety for healthy clients [3].
Extremely high detection efficiency for common cancers in Vietnam: For groups of cancers with the highest incidence and mortality rates, the test demonstrates extremely strong clinical sensitivity:
Breast Cancer: Sensitivity reached 96.8% [3].
Liver Cancer: Sensitivity reached 94.5% [3].
Gastric Cancer: Sensitivity reached 93.5% [3].
Lung Cancer: Sensitivity reached 93.3% [3].
Colorectal Cancer: Sensitivity reached 86.7% [3].
Rapid turnaround time: The optimized biological data analysis process at the central laboratory enables the delivery of comprehensive analysis results to clinicians and clients within just 7–14 working days, reducing the waiting time and anxiety to ensure timely intervention during the “golden window” [3].
MEDICAL GUIDANCE: WHO SHOULD UNDERGO THIS TEST?
Non-invasive testing, utilizing a simple peripheral blood draw technique (10 - 20mL), is recommended by medical professionals for routine performance among the following groups:
Individuals aged 40 and older (the stage where mutation and cancer incidence rates begin to rise sharply according to age-related charts).
Individuals with a family history (grandparents, parents, siblings) of cancer.
Individuals with lifestyle and environmental risk factors: Active or passive smoking, alcohol abuse, overweight or obesity, chronic Hepatitis B or C infection, or frequent exposure to toxic chemicals in the workplace.
Anyone with a proactive health consciousness, desiring to establish the most comprehensive and accurate cancer prevention map for themselves.
Do not wait for cancer to speak before seeking a solution. Take charge of your proactive health with world-leading genetic decoding technology at the American International Hospital (AIH) today!
MEDICAL REFERENCE LIST (AMA 11TH EDITION)
Ministry of Health of Vietnam. Report on the Status of Cancer Prevention and Control in Vietnam. Hanoi: Ministry of Health of Vietnam; 2024.
American Cancer Society. Cancer Facts & Figures 2024. Atlanta, GA: American Cancer Society; 2024.
Leong CO, Tan BS, Toh HC, et al. Abstract 1113: Clinical validation of a targeted multi-cancer early detection (MCED) test using cfDNA mutation and integrated genomic signatures analysis. Cancer Res. 2026;86(7_Supplement):1113. doi:10.1158/1538-7445.AM2026-1113.
Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. doi:10.1016/j.bdq.2019.100087.
Li W, Luo S, He K, et al. Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests. Front Oncol. 2024;14:1418898. doi:10.3389/fonc.2024.1418898.
Jain S, Po-Bascuñan P, Makarem M, et al. Machine Learning Transforms Multicancer Detection Tests. Target Oncol. 2025;20(2):161-168. doi:10.1007/s11523-025-01123-x.
--------------------
Leave a comment